We performed a retrospective analysis of patients with BRAF‐mutated metastatic melanoma treated with BRAF/MEK inhibition therapy or anti‐PD‐1 monotherapy (nivolumab or pembrolizumab). The gene discussed is MAP2K7; the disease is metastatic melanoma.